Nasdaq: BCTX
Positioned for a ~2.5B Opportunity
Featured in Nature Medicine
BriaCell Phase 3 trial featured in Nature Medicine as “Eleven clinical trials that will shape medicine in 2026”
Signals in Hard-to-Treat patients
The deck highlights clinical benefit in heavily pre-treated patients, including those resistant to other advanced treatment categories.ck desig
Investment Highlights
▪ Lead drug candidate Bria-IMT™
➢ Pivotal Phase 3 study underway in metastatic breast cancer (over 40K US deaths/year)
➢ Phase 2 study demonstrated 2-fold increase in survival vs comparable patients in the literature
➢ Unprecedented clinical benefit in checkpoint inhibitor (CPI) and antibody-drug conjugate (ADC) resistant patients
➢ Remarkable clinical efficacy in patients with central nervous system (CNS) metastases
➢ Awarded Fast Track designation by FDA
➢ Single agent and combination check point inhibitor (+ CPI) activity
▪ Bria-OTS & Bria-OTS+ : Next generation, cell-based cancer immunotherapy platform
➢ Ongoing Phase 1/2a study in breast cancer
➢ Bucket trial with other cancer indications to be added
➢ Next generation prostate cancer candidate scheduled to enter clinic 2025
➢ National Cancer Institute SBIR awards
➢ Bria-OTS+ more potent version of Bria-OTS
Bria-IMT: Lead Candidate
▪ Bria-IMT - a cell based, patented, targeted immunotherapy
▪ Derived from a well characterized breast cancer cell line
▪ Expresses tumor antigens and GM-CSF to activate cancer fighting CD4+ and CD8+ T cells
▪ Stimulates the immune system to enhance targeted killing of cancer cells
▪ Off-the-shelf approach easy to distribute and administer
➢ Cells are grown (cGMP), harvested, irradiated and cryopreserved for shipment to clinical sites where they are thawed and injected intradermally (upper back and thighs)
Learn More About BriaCell Therapeutics